Standard Biotools Inc. (LAB): Total Liabilities
$143.46M
As of 2025-12-31
$87.25M
As of 2026-06-30
-3.7%
3-year compound annual growth
-5.0%
5-year compound annual growth
-5.6%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $143.46M | +2.0% | 2026-03-16, Balance as of period end |
| 2024-12-31 | $140.62M | -12.0% | 2026-03-16, Balance as of period end |
| 2023-12-31 | $159.87M | -0.4% | 2025-03-11, Balance as of period end |
| 2022-12-31 | $160.52M | -11.1% | 2024-03-01, Balance as of period end |
| 2021-12-31 | $180.62M | -2.7% | 2023-03-14, Balance as of period end |
| 2020-12-31 | $185.71M | +67.0% | 2022-03-08, Balance as of period end |
| 2019-12-31 | $111.20M | -52.0% | 2021-02-25, Balance as of period end |
| 2018-12-31 | $231.53M | -9.7% | 2020-02-27, Balance as of period end |
| 2017-12-31 | $256.42M | +1.3% | 2019-03-18, Balance as of period end |
| 2016-12-31 | $253.16M | -0.8% | 2018-03-08, Balance as of period end |
| 2015-12-31 | $255.15M | -0.8% | 2017-03-03, Balance as of period end |
| 2014-12-31 | $257.14M | n/m | 2016-02-29, Balance as of period end |
| 2013-12-31 | $20.50M | +56.8% | 2015-02-26, Balance as of period end |
| 2012-12-31 | $13.07M | -41.7% | 2014-03-12, Balance as of period end |
| 2011-12-31 | $22.43M | -23.8% | 2013-03-12, Balance as of period end |
| 2010-12-31 | $29.42M | n/a | 2012-03-26, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Standard Biotools Inc. (LAB) | 2025-12-31 | $143.46M | +2.0% |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | $213.39M | +126.2% |
| Nurix Therapeutics, Inc. (NRIX) | 2025-11-30 | $149.39M | +4.9% |
| Cytokinetics Inc (CYTK) | 2025-12-31 | $2.08B | +35.6% |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | $57.16M | -44.6% |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | $508.98M | -3.0% |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $65.96M | +27.6% |
| Siga Technologies Inc (SIGA) | 2025-12-31 | $20.65M | -27.6% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $52.56M | -56.6% |
Compare LAB, SPRY, NRIX, CYTK side by side · Screen every company in Pharmaceutical Preparations ↗